Seaport Therapeutics Targets $212 Million in US Public Debut

Seaport Therapeutics Inc. is preparing to enter the public markets, seeking to raise $212.4 million through an initial public offering in the United States. The clinical-stage biotechnology company, headquartered in Boston, specializes in the development of treatments for depression and anxiety. The move comes as the company seeks to capitalize on the growing demand for mental health therapeutics. By transitioning to a public entity, Seaport aims to secure the necessary capital to advance its clinical trials and move its drug candidates closer to regulatory approval. According to the filing submitted to the US Securities and Exchange Commission, Seaport plans to offer 11.8 million shares. The company has set a target price range of $16 to $18 per share. If the offering is priced at the top end of the range, Seaport Therapeutics would achieve a market valuation of approximately $912 million, based on the total outstanding shares disclosed in the SEC documentation. While the IPO is a significant milestone for the Boston biotech firm, it reflects a broader trend of clinical-stage companies seeking public funding to sustain high research and development costs associated with psychiatric medicine.